濟民製藥(603222.SH)半年度淨利潤降55.64%至1084.82萬元
格隆匯 8 月 20日丨濟民製藥(603222.SH)發佈2020年半年度報告,實現營業收入3.43億元,同比下降9.48%;歸屬於上市公司股東的淨利潤1084.82萬元,同比下降55.64%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1316.99萬元,同比下降32.31%;基本每股收益0.03元。
2020年上半年,突如其來的“新冠肺炎”傳播和流行已經成為全球公共衞生重大事件。在此大背景下,一方面,身處疫情重災區的鄂州二醫院全力配合當地政府及衞健委的工作指示及調度,積極抗疫,期間累計收治各類發熱、肺炎病例236例,確診病例153例;另一方面,公司各業務條線抓好防疫和員工返廠工作,加緊復工復產,隨着國內“新冠肺炎”疫情的逐步控制,二季度以來,公司各項業務快速恢復,在安全注射器及新冠病毒檢測試劑盒產品銷售增長的帶動下,公司第二季度實現營業收入21142.24萬元,扣非淨利潤2372.03萬元,較2019年同期分別增長了13.50%和123.50%,扭轉了一季度業績虧損的局面,並帶動公司半年度實現扣非淨利潤1316.99萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.